Supernus Pharmaceuticals (SUPN) Goodwill & Intangibles (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Goodwill & Intangibles of $588.9 million for Q2 2026, down 1.58% year-over-year from $598.3 million in Q2 2025, and down 12.16% on a QoQ basis from $670.4 million in Q1 2026.
Supernus Pharmaceuticals (SUPN) Goodwill & Intangibles (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Goodwill & Intangibles for 16 years, with the latest figure at $588.9 million in Q2 2026.
- Goodwill & Intangibles for Q2 2026 came in at $588.9 million, down 1.58% year-over-year; the trailing twelve-month figure through Jun 2026 was $588.9 million (down 1.58% YoY), and the FY2025 annual result was $694.3 million, up 8.67% from the prior year.
- Goodwill & Intangibles retreated to $588.9 million in Q2 2026, from $670.4 million in the prior quarter.
- Over five years, Goodwill & Intangibles peaked at $879.5 million in Q1 2022 and troughed at $588.9 million in Q2 2026.
- A 5-year average of $724.2 million and a median of $706.8 million in 2023 frame the typical range for Goodwill & Intangibles.
- The widest annual swing landed in 2022, when Goodwill & Intangibles surged 101.41%; it then fell 13.32% in 2024.
- A 5-year view of Goodwill & Intangibles shows it stood at $819.5 million in 2022, then retreated by 12.52% to $716.9 million in 2023, then fell by 10.88% to $638.9 million in 2024, then advanced by 8.67% to $694.3 million in 2025, then fell by 15.19% to $588.9 million in 2026.
- Per Business Quant data, the three most recent Goodwill & Intangibles figures were $588.9 million in Q2 2026, $670.4 million in Q1 2026, and $694.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.37 Bn | 185.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 588.89 Mn |
| Mar 31, 2026 | 670.38 Mn |
| Dec 31, 2025 | 694.34 Mn |
| Sep 30, 2025 | 742.56 Mn |
| Jun 30, 2025 | 598.33 Mn |
| Mar 31, 2025 | 619.15 Mn |
| Dec 31, 2024 | 638.93 Mn |
| Sep 30, 2024 | 657.18 Mn |
| Jun 30, 2024 | 676.66 Mn |
| Mar 31, 2024 | 696.77 Mn |
| Dec 31, 2023 | 716.91 Mn |
| Sep 30, 2023 | 758.17 Mn |
| Jun 30, 2023 | 779.41 Mn |
| Mar 31, 2023 | 799.52 Mn |
| Dec 31, 2022 | 819.48 Mn |
| Sep 30, 2022 | 840.14 Mn |
| Jun 30, 2022 | 858.82 Mn |
| Mar 31, 2022 | 879.46 Mn |
| Dec 31, 2021 | 902.21 Mn |
| Sep 30, 2021 | 424.58 Mn |